Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of ($12.83), $1.13 worse than the analyst estimate of ($11.70). Revenue for the quarter came in at $2.65 billion versus the consensus estimate of $2.66 billion.

GUIDANCE:

Vertex Pharma sees FY2024 revenue of $10.65-10.85 billion, versus the consensus of $10.762 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.